Connect with us
nairametrics

Coronavirus

AstraZeneca suspends COVID-19 vaccine final stage trial over safety concerns

AstraZeneca’s COVID-19 vaccine is being developed in collaboration with University of Oxford.

Published

on

AstraZeneca suspends COVID-19 vaccine final stage trial over safety concerns, COVID-19: J&J starts vaccine trials on humans after success on monkeys

AstraZeneca Plc has suspended a final-stage trial of one of the leading Covid-19 vaccine candidates, after a suspected serious adverse reaction on one of the participants.

This was disclosed by a health news website, Stat News, on Tuesday, September 8, 2020, while quoting an AstraZeneca spokesperson.

The AstraZeneca official said, “Standard review process triggered a pause to vaccination to allow the review of safety data.”

AstraZeneca, in a statement, said that the trial was put on hold to conduct a standard review of the drugmaker’s vaccine trials after one person developed an unexplained illness. The pharmaceutical company said that this was intended to give researchers time to examine safety data while maintaining the integrity of the trials

READ: Moderna to supply 80 million doses of its COVID-19 vaccine to European Union

GTBank 728 x 90

This study is testing a Covid-19 vaccine which is being developed by AstraZeneca in collaboration with University of Oxford researchers at various sites, including the United Kingdom, where this adverse reaction was reported.

The media report suggests that although the participant is expected to recover, details of the nature of the case and when it happened were not given.

Stat news said that the suspension of the trial has affected other vaccine trials by AstraZeneca as well as clinical trials being conducted by other vaccine makers, who are looking for signs of similar reactions.

Coronation ads

READ: Moderna vaccine certified to protect monkeys against Coronavirus during study

The AstraZeneca spokesperson’s statement reads, “In large trials, illnesses will happen by chance but must be independently reviewed to check this carefully.”

Stat News reported that serious adverse reactions from the trials could have various outcomes such as issues that require hospitalization, life-threatening illness and death.

It can be recalled that 9 leading US and European vaccine developers, which include AstraZeneca, Pfizer Inc and GlaxoSmithKline, pledged on Tuesday to ensure scientific safety and efficacy standards for their vaccine candidates despite the alleged political pressure and urgency to contain the coronavirus pandemic.

Jaiz bank ads

Chike Olisah is a graduate of accountancy with over 15 years working experience in the financial service sector. He has worked in research and marketing departments of three top commercial banks. Chike is a senior member of the Nairametrics Editorial Team. You may contact him via his email- [email protected]

Click to comment

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Coronavirus

COVID-19: AstraZeneca vaccine could be 90% effective against the virus

AstraZeneca has said that its vaccine being developed in collaboration with the University of Oxford could be 90% effective.

Published

on

AstraZeneca suspends COVID-19 vaccine final stage trial over safety concerns, COVID-19: J&J starts vaccine trials on humans after success on monkeys

British pharmaceutical company, AstraZeneca, announced that the COVID-19 vaccine it is developing with Oxford University is 90% effective and also prevented 70% of trialists from falling ill.

This was disclosed by AstraZeneca on Monday and reported by Reuters and Bloomberg. AstraZeneca said its vaccine was 90% effective when a half dose was issued, followed by a full dose 30 days later.

AstraZeneca joins other major pharmaceutical companies including Pfizer and Moderna in the race to develop a vaccine for the pandemic.

What they are saying

Oxford University said it could be 70.4% effective and tests on two dose regimes show that it could be is 90%.

GTBank 728 x 90
Interim data shows the #OxfordVaccine is 70.4% effective and tests on two-dose regimens show that it could be 90%, moving us one step closer to supplying it at low cost around the world,” they announced on social media. Monday’s announcement came after trial data was released in the UK and Brazil.
“We see a lot of merit in this regimen and we will now start discussions with regulators into incorporating this dose combination for further clinical investigation,” an Astra spokesman told Bloomberg.
Chief Executive, Pascal Soriot, said: “This vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency.

The company expects to have up to 200 million doses by the end of the year and produce up to 700 million doses by the first quarter of 2021.

The new vaccine also answers issues of vaccine storage and distribution, as it can be kept at basic refrigerator temperature for transport, making it much easier to transport, compared to Moderna and Pfizer’s vaccines.

What you should know 

Coronation ads

Nairametrics reported earlier this month that Pfizer Inc disclosed that its experimental vaccine, which is jointly developed with BioNTech was more than 90% effective in preventing COVID-19, based on initial data from a large study, in the ongoing phase 3 trials.

Last week, Pharmaceutical company, Moderna Inc, stated its COVID-19 vaccine is 94.5% effective in treating coronavirus, after preliminary analysis of a large late-stage clinical trial.

Continue Reading

Coronavirus

COVID-19: G-20 to extend debt relief to developing nations

The G-20 has endorsed a plan which will enable the freezing of debt obligations to developing nations.

Published

on

Kristalina Georgieva, IMF boss hints at 'synchronized slowdown' in global growth , IMF: 40% of African countries can't pay back their debts , Nigeria worse off, posts grows lower than LIDC benchmark - IMF, Measures introduced by Nigeria to ensure transparent use of the $3.4b IMF loan

The G-20, in a bid to combat the economic fallouts of the pandemic, has endorsed a plan which will enable the freezing of debt obligations to developing nations till mid-2021.

This was reported by Reuters after the group met over the weekend to discuss vaccine relief and other pressing issues. They also agreed on a common approach to dealing with debt relief.

The G-20 leaders announced in a communique urging private creditors to extend debt relief to nations that are eligible for the initiative.

READ: Africa seeking extra $44 billion to deal with COVID-19 pandemic

What they are saying

GTBank 728 x 90

The Head of the International Monetary Fund, Kristalina Georgieva, urged that the world still runs the risk of falling into another crisis and called for closer cooperation through faster integration of the G-20 Framework. She added that the G-20’s efforts in combating the pandemic have helped soften the economic fallout caused by covid-19.

“The world is not out of the woods yet in terms of this crisis. Cooperation is going to be even more important going forward,” she said.

READ: Nigeria to generate $6 billion through Blockchain by 2030-NITDA

Coronation ads

“We must also help those countries not covered by the Framework to address debt vulnerabilities, so that their economies can become more resilient,” she added.

What you should know 

Nairametrics reported that the G-20 met earlier this weekend and agreed to announce a pledge to pay for vaccine distribution to developing nations that can’t afford it. The leaders also discussed a debt extension programme to developing nations during the weekend’s G-20 summit.

READ: Largest private investment in Africa begins $15 billion financing

In April 2020, Ministers of Finance from African countries requested debt relief from bilateral, multilateral, and commercial partners to cushion the negative impact of the coronavirus.

Jaiz bank ads

(READ MORE: Covid-19: Nigeria to seek $750 million from World Bank- Finance Minister)

Stanbic IBTC

Last Month, Nairametrics reported that the total external debt of the least developed countries under the Debt Service Suspension Initiative (DSSI) has increased by 9.55% to $744 billion in 2019. This was disclosed in the World Bank’s International Debt Statistics 2021.

The global Debt Service Suspension Initiative by rich nations made it eligible for 73 countries to have their debt frozen. However, only 46 countries took part in the initiative, freezing up to 5.7 billion in 2020 debt service payments.

Continue Reading

Coronavirus

COVID-19 Update in Nigeria

On the 22nd of November 2020, 155 new confirmed cases and 1 death was recorded in Nigeria

Published

on

The spread of novel Corona Virus Disease (COVID-19) in Nigeria continues to record significant increases as the latest statistics provided by the Nigeria Centre for Disease Control reveal Nigeria now has 66,383 confirmed cases.

On the 22nd of November 2020, 155 new confirmed cases and 1 death was recorded in Nigeria, having carried out a total daily test of 4,083 samples across the country.

To date, 66,383 cases have been confirmed, 62,076 cases have been discharged and 1,167 deaths have been recorded in 36 states and the Federal Capital Territory. A total of 743,298 tests have been carried out as of November 22nd, 2020 compared to 739,215 tests a day earlier.

COVID-19 Case Updates- 22nd November 2020,

  • Total Number of Cases – 66,383
  • Total Number Discharged – 62,076
  • Total Deaths – 1,167
  • Total Tests Carried out – 743,298

According to the NCDC, the 155 new cases are reported from 12 states- Lagos (60), Katsina (37), Kaduna (35), FCT (6), Ogun (4), Edo (3), Kwara (3), Rivers(2), Kano (2), Jigawa (1), Oyo (1) and Taraba (1).

Meanwhile, the latest numbers bring Lagos state total confirmed cases to 22,962, followed by Abuja (6,498), Plateau (3,800), Oyo (3,703), Rivers (2,956), Kaduna (2,895), Edo (2,694), Ogun (2,153), Delta (1,823), Kano (1,773), Ondo (1,727), Enugu (1,332),  Kwara (1,091), Ebonyi (1,055), Katsina (1,007), Osun (945), Gombe (938). Abia (926), Bauchi (753), and Borno (745).

GTBank 728 x 90

Imo State has recorded 662  cases, Benue (493), Nasarawa (485), Bayelsa (445),  Ekiti (353), Jigawa (328), Akwa Ibom (319), Niger (295), Anambra (285), Adamawa (261), Sokoto (165), Taraba (156), Kebbi (93), Yobe (92), Cross River (90), Zamfara (79), while Kogi state has recorded 5 cases only.

READ ALSO: COVID-19: Western diplomats warn of disease explosion, poor handling by government

Lock Down and Curfew

In a move to combat the spread of the pandemic disease, President Muhammadu Buhari directed the cessation of all movements in Lagos and the FCT for an initial period of 14 days, which took effect from 11 pm on Monday, 30th March 2020.

Coronation ads

The movement restriction, which was extended by another two-weeks period, has been partially put on hold with some businesses commencing operations from May 4. On April 27th, 2020, Nigeria’s President, Muhammadu Buhari declared an overnight curfew from 8 pm to 6 am across the country, as part of new measures to contain the spread of the COVID-19. This comes along with the phased and gradual easing of lockdown measures in FCT, Lagos, and Ogun States, which took effect from Saturday, 2nd May 2020, at 9 am.

On Monday, 29th June 2020 the federal government extended the second phase of the eased lockdown by 4 weeks and approved interstate movement outside curfew hours with effect from July 1, 2020. Also, on Monday 27th July 2020, the federal government extended the second phase of eased lockdown by an additional one week.

On Thursday, 6th August 2020 the federal government through the secretary to the Government of the Federation (SGF) and Chairman of the Presidential Task Force (PTF) on COVID-19 announced the extension of the second phase of eased lockdown by another four (4) weeks.

READ ALSO: Bill Gates says Trump’s WHO funding suspension is dangerous

 

Jaiz bank ads

Stanbic IBTC

 

 

 

Continue Reading